Starting from the observation that higher DOT1L levels strongly correlated with breast cancer progression, preliminary experiments indicated that its pharmacological inhibition by EPZ00477 and SYC-522, a potent new generation DOT1L inhibitor (Liu et al., 2014), reduced BC cell proliferation and induced cancer stem cells differentiation (Zhang et al., 2014). The gene discussed is DOT1L; the disease is cancer.